LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study



Status:Terminated
Conditions:Women's Studies
Therapuetic Areas:Reproductive
Healthy:No
Age Range:18 - 80
Updated:4/17/2018
Start Date:June 2014
End Date:March 2015

Use our guide to learn which trials are right for you!

An Open-Label, Randomized Study to Determine the Safety and Efficacy of LUXSOL(TM) Cream for the Treatment of Bacterial Vaginosis: A Proof of Concept Study

LUXSOL Cream may be useful for the treatment of bacterial Vaginosis. In this study, LUXSOL
Cream is compared to a control arm group using metronidazole cream. LUXSOL is administered
intravaginally for 10 days, each evening before bedtime to treat bacterial Vaginosis..

LUXSOL Topical Cream is a copper containing topical cream indicated for the treatment of
bacterial vaginosis (BV). The study is an open-label, randomized, controlled study comparing
LUXSOL Cream to Metrogel in patients with a diagnosis of BV. The investigational product or
the comparator product will be self-administered by the patient for 10 consecutive nights. A
successful patient outcome is cured BV at 30 days.

Inclusion Criteria:

- Subject agrees to participate and signs informed consent

- Female age 18 or older

- Subject has clinical BV with 4 of 4 Amsel's criteria

- Off-white (milky or gray), thin, adherent, homogenous discharge with minimal or absent
pruritus and inflammation of the vulva and vagina

- Presence of 'clue cells' >/=20% of the total epithelial cells on microscopic
examination of the saline 'wet mount.'

- Virginal secretion pH of >4.5

- A fishy odor of the vaginal discharge with the addition of a drop of 10% KOH (i.e. a
positive 'whiff test')

- Subject agrees to refrain from use of douches, intravaginal products for treatment
period

- Subject agrees to refrain from taking oral or intravaginal antibiotics or antifungal
agents during entire study period

- Subject agrees to refrain from vaginal intercourse during treatment period.

Exclusion Criteria:

- Subject has another infectious or noninfectious cause of vulvovaginitis

- Subject has another vaginal or vulvar condition that would confound the determination
of study endpoints.

- Subject has received antifungal or antimicrobial therapy (systemic or intravaginal)
within the last 14 days prior to enrollment.

- Subject is under treatment for cervical intra-epithelial neoplasia or cervical
carcinoma

- Subject is known to be HIV positive

- Subject has a positive pregnancy test

- Subject has any abnormal anatomy or pathology of the vagina

- Subject has untreated sexually transmitted disease

- Subject is currently having menstrual period or may have her period during treatment
days.

- Subject's PAP smear >/= to LSIL

- Subjects with known sensitivity or allergic reactions to copper or Metronidazole
vaginal gel

- Subject has known Wilson's disease
We found this trial at
2
sites
Philadelphia, Pennsylvania 19140
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials